Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma

Trial Profile

Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Bortezomib; Bortezomib; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jan 2017 Status changed from recruiting to completed.
    • 24 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top